Skip to content

Outcomes From Treatment Liver and Bile Duct Diseases

Evaluation of Outcomes From Treatment of Benign or Malignant Liver and Bile Duct Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04637243
Enrollment
126
Registered
2020-11-19
Start date
2023-03-09
Completion date
2026-12-31
Last updated
2026-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign or Malignant Liver and Bile Duct Disease

Brief summary

It is reported in the literature that the treatment of any liver and bile duct disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. Our goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality and morbidity. The main aim of this study is to evaluate and compare the outcomes from our multiple treatments of benign or malignant liver and bile duct diseases.

Detailed description

The study will be a retrospective chart review of patients who have been diagnosed with benign or malignant liver and bile duct disease under the practices of Rohan Jeyarajah, M.D., Houssam Osman, M.D., F.A.C.S., Edward Cho, M.D., Sc.M at Methodist Health System Hospital in Richardson, T.X. We plan to conduct an analysis of patients meeting the inclusion criteria form 2005 to present (up to the day before this study receives IRB approval). Charts will also be reviewed by the PI. Sub-I, Fellows, Office Staff, Clinical Research Coordinator who are delegated to do so by the PI. Data will be obtained from a national database. Data will be analyzed primarily by the study conductors.

Interventions

OTHERTreatment of Benign or Malignant Liver and Bile Duct Diseases

Available treatment of Benign or Malignant Liver and Bile Duct Diseases

Sponsors

Methodist Health System
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients diagnosed and treated for liver and bile duct disease benign or malignant from 2005 to present (up to the day before this study receives IRB approval) * Age \> 18 years

Exclusion criteria

* Patients that are not diagnosed with or treated for liver and bile duct disease * Age \< 18 years

Design outcomes

Primary

MeasureTime frameDescription
Mortality from Treatment of Benign or Malignant Liver and Bile Duct Diseases2005 to 2019Mortality
Morbidity from Treatment of Benign or Malignant Liver and Bile Duct Diseases2005 to 2019Morbidity

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDhiresh Jeyarajah, M.D.

Trinity Surgical Consultants, Methodist Richardson Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 11, 2026